We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis.
- Authors
Horiuchi, Kohei; Ikemura, Shinnosuke; Sato, Takashi; Shimozaki, Keitaro; Okamori, Satoshi; Yamada, Yoshitake; Yokoyama, Yoichi; Hashimoto, Masahiro; Jinzaki, Masahiro; Hirai, Ikuko; Funakoshi, Takeru; Mizuno, Ryuichi; Oya, Mototsugu; Hirata, Kenro; Hamamoto, Yasuo; Terai, Hideki; Yasuda, Hiroyuki; Kawada, Ichiro; Soejima, Kenzo; Fukunaga, Koichi
- Abstract
Background Immune checkpoint inhibitors (ICIs) have demonstrated efficacy over previous cytotoxic chemotherapies in clinical trials among various tumors. Despite their favorable outcomes, they are associated with a unique set of toxicities termed as immune-related adverse events (irAEs). Among the toxicities, ICI-related pneumonitis has poor outcomes with little understanding of its risk factors. This retrospective study aimed to investigate whether pre-existing interstitial lung abnormality (ILA) is a potential risk factor for ICI-related pneumonitis. Materials and Methods Patients with non-small cell lung cancer, malignant melanoma, renal cell carcinoma, and gastric cancer, who was administered either nivolumab, pembrolizumab, or atezolizumab between September 2014 and January 2019 were retrospectively reviewed. Information on baseline characteristics, computed tomography findings before administration of ICIs, clinical outcomes, and irAEs were collected from their medical records. Pre-existing ILA was categorized based on previous studies. Results Two-hundred-nine patients with a median age of 68 years were included and 23 (11.0%) developed ICI-related pneumonitis. While smoking history and ICI agents were associated with ICI-related pneumonitis (P =.005 and.044, respectively), the categories of ILA were not associated with ICI-related pneumonitis (P =.428). None of the features of lung abnormalities were also associated with ICI-related pneumonitis. Multivariate logistic analysis indicated that smoking history was the only significant predictor of ICI-related pneumonitis (P =.028). Conclusion This retrospective study did not demonstrate statistically significant association between pre-existing ILA and ICI-related pneumonitis, nor an association between radiologic features of ILA and ICI-related pneumonitis. Smoking history was independently associated with ICI-related pneumonitis. Further research is warranted for further understanding of the risk factors of ICI-related pneumonitis.
- Subjects
RISK factors of pneumonia; THERAPEUTIC use of monoclonal antibodies; LUNG cancer; PNEUMONIA; RENAL cell carcinoma; STOMACH tumors; IMMUNE checkpoint inhibitors; MELANOMA; LUNGS; MULTIVARIATE analysis; MULTIPLE regression analysis; ANTINEOPLASTIC agents; INTERSTITIAL lung diseases; RETROSPECTIVE studies; ACQUISITION of data; LUNG tumors; RISK assessment; NIVOLUMAB; MEDICAL records; COMPUTED tomography; DRUG side effects; SMOKING; DISEASE complications
- Publication
Oncologist, 2024, Vol 29, Issue 1, pe108
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1093/oncolo/oyad187